{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-211337","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2021-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.064708+00:00","generated_at":"2026-06-30T06:23:27.066179+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Verrica Pharmaceuticals appoints Terry Kohler as CFO, replacing Brian Davis effective July 16, 2021","bullets":["Brian Davis terminated as CFO effective July 16, 2021; eligible for severance subject to separation agreement.","Terry Kohler appointed CFO effective July 16, 2021; previously VP of Corporate Development and Treasurer at Endo.","Kohler receives $350,000 base salary, 40% target bonus, and option to purchase 125,000 shares vesting over 4 years.","Kohler holds an MBA from UNC Chapel Hill and is a Certified Management Accountant.","Employment at-will; severance provisions vary based on timing and change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-211337","json":"https://secwatch.observer/filing/0001193125-21-211337.json","markdown":"https://secwatch.observer/filing/0001193125-21-211337.md","text":"https://secwatch.observer/filing/0001193125-21-211337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521211337/0001193125-21-211337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521211337/d181869d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T06:23:27.066179+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d0c3594f2","claim":"Brian Davis was terminated as Chief Financial Officer at Verrica Pharmaceuticals Inc..","evidence_excerpt":"On July 6, 2021, Verrica Pharmaceuticals Inc. (the “Company”) notified Brian Davis that his employment as Chief Financial Officer of the Company would terminate, effective as of July 16, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521211337/0001193125-21-211337-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a395170db2","claim":"Terry Kohler was appointed as Chief Financial Officer at Verrica Pharmaceuticals Inc..","evidence_excerpt":"On July 8, 2021 the board of directors (the “Board”) of the Company appointed Terry Kohler as the Company’s Chief Financial Officer, effective as of July 16, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521211337/0001193125-21-211337-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}